Stocks in Action USA: ImmunityBio, AST SpaceMobile, Micron Technology
Reading Time: 3 minutes
ImmunityBio (IBRX) – Biotech stock explodes thanks to revenue potential and encouraging cancer data! The stock of ImmunityBio continues its extreme rally, rising double digits again in pre-market trading after a significant jump the previous day. The driver is a combination of rapidly growing revenue prospects and positive clinical data: The company anticipates a revenue surge with its cancer drug Anktiva of around 700% to approximately $113 million by 2026. Additional excitement comes from international expansion after the Saudi Arabian pharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
